www.medical-devices.tech
06
'23
Written on Modified on
Stratasys News
STRATASYS AND COLLPLANT COLLABORATE ON BIOPRINTING OF TISSUES AND ORGANS
The joint development and commercialization agreement will initially focus on the development of a bioprinting solution for CollPlant’s regenerative breast implants.
Human-size breast implant, printed with Stratasys P3 3D printing technology and CollPlant's bioink.
Stratasys Ltd. and CollPlant Biotechnologies recently announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant's regenerative breast implants program.
The new bioprinter, based on Stratasys’ precise P3™ 3D printing technology in combination with CollPlant's flagship bioinks, will enable the production of CollPlant’s state-of-the-art breast implants, which are being designed to regenerate an individual’s natural breast tissue without eliciting immune response, providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.
Under the agreement, both companies have agreed to cross-promote each other’s bioprinting products. Stratasys’ bioprinter will be offered to customers together with CollPlant’s bioinks, and similarly, Stratasys’ bioprinter will be offered to CollPlant’s business partners and customers.
In January 2023, CollPlant announced that it successfully completed a large-animal study for its 3D bioprinted regenerative breast implants. The preclinical study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. Based on these positive results, CollPlant is planning to initiate a follow-up, large-animal study in the second half of 2023 using commercial-size implants to support subsequent human studies and future product commercialization.
Stratasys Ltd. and CollPlant Biotechnologies recently announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant's regenerative breast implants program.
The new bioprinter, based on Stratasys’ precise P3™ 3D printing technology in combination with CollPlant's flagship bioinks, will enable the production of CollPlant’s state-of-the-art breast implants, which are being designed to regenerate an individual’s natural breast tissue without eliciting immune response, providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.
Under the agreement, both companies have agreed to cross-promote each other’s bioprinting products. Stratasys’ bioprinter will be offered to customers together with CollPlant’s bioinks, and similarly, Stratasys’ bioprinter will be offered to CollPlant’s business partners and customers.
In January 2023, CollPlant announced that it successfully completed a large-animal study for its 3D bioprinted regenerative breast implants. The preclinical study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. Based on these positive results, CollPlant is planning to initiate a follow-up, large-animal study in the second half of 2023 using commercial-size implants to support subsequent human studies and future product commercialization.
www.stratasys.com
